Abbott Laboratories has recently introduced a fluorescent polarization inununoassay kit for detection of amphetamine and methamphetamine in urine for use on the Abbott TDx. With these reagents, Abbott has successfully eliminated most of the cross reactivity with other sympathomimetic aniines and similar compounds often observed in other immunoassays (1). However, we have noted that the TDx amphetainine/methamphetamine kit does cross react signif. icantly with 3,4-methylenedioxymethamphetamine (MDMA), also known as "Ecstasy," and 3,4-methylenedioxyamphetamine (MBA).
Box 597 MCV Station, Richmond, VA 23298) Abbott Laboratories has recently introduced a fluorescent polarization inununoassay kit for detection of amphetamine and methamphetamine in urine for use on the Abbott TDx. With these reagents, Abbott has successfully eliminated most of the cross reactivity with other sympathomimetic aniines and similar compounds often observed in other immunoassays (1). However, we have noted that the TDx amphetainine/methamphetamine kit does cross react signif. icantly with 3,4-methylenedioxymethamphetamine (MDMA), also known as "Ecstasy," and 3,4-methylenedioxyamphetamine (MBA).
A 25-year-old woman was brought to the emergency room by her husband, who admitted that his wife had been using Ecstasy. During the drug screen for this patient, results of an amphetamine/methamphetainine fluorescent polarization were positive. GC/MS analysis of an alkaline extract of the urine sample (2) confirmed the presence of MDMA and, in addition, ruled out the presence of amphetamine or methamphetamine.
To confirm this suspected crossreactivity of TDx reagents with MDMA, we tested, with the Abbott kit, urine from a rat given 40 mg of MDMA per kilogram, subcutaneously. MBA is reportedly a major metabolite of MDMA in rats and is suspected to be so in humans as well (3). This rat urine contained both the parent MDMA and its metabolite MBA, and yielded a "HF' positive with the kit.
To determine the percent cross reactivity of both MDMA and MBA with the Abbott reagents, we supplemented blank human urine with MDMA or MDA in the concentrations listed in Table 1 , calibrated the instrument, and assayed the samples. Percent cross reactivity was calculated as follows: (concn. detected by TDxiactual concn of drug) x 100 = percent cross reactivity As Table 1 shows, the percent cross reactivity for MBMA tends to be greater for lower concentrations-the crossreactivity pattern seen in all TDx drug-of-abuse assays (1). For MBA, however, the cross reactivity is apparently very high at all concentrations, indicating that the assay is very sensitive for this compound. In fact, the sensitivity of the Abbott antibody with MBA is approximately equal to its reactivity with equivalent concentrations of the d-and 1-isomers of amphetamine and methainphetaniune. In one reported case of nonfatal overdose with MDMA, concentrations of the drug in urine were 410 g/mL 1 h after admission to the hospital and 816 pg/mL the day after admission (4). In MBA-related deaths, urine concentrations have ranged from 2 to 175 g/mL (5) . Clearly, these concentrations would have yielded positive results with the Abbott reagents, given the data in Table 1 .
Although MBMA was classified as a schedule I controlled substance in 1985 and MBA was so classified years earlier, they continue to be widely abused (6) and have been implicated in several deaths (5-7) . In addition, MDMA and MBA abuse no longer seems to be confined to only certain geographical areas. Thus we believe that the crossreactivity of the Abbott reagents with these compounds is actually a desirable feature; certainly, the presence of MBMA or MDA in a sample may be a significant finding. It is important, however, that analysts be aware that a positive result with Abbott TDx amphetamine/methamphetamine reagents may actually be due to the presence of MBMA or MBA.
